Overview

Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Status:
Terminated
Trial end date:
2018-10-22
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled, randomized, double-blind, multicenter, parallel-group comparison study in primary biliary cholangitis participants inadequately responding to ursodeoxycholic acid.
Phase:
Phase 2
Details
Lead Sponsor:
EA Pharma Co., Ltd.
Treatments:
Quetmolimab
Ursodeoxycholic Acid